Estrogen-bridged purines: A new series of anti-tumor agents which alter cell membrane properties

An estrogen-bridged adenine derivative was equitoxic to both the P388 murine leukemia and an adriamycin-resistant subline, $\text{P388}\text{ADR}$. The drug rapidly altered several P388 and $\text{P388}\text{ADR}$ membrane properties resulting in impaired nucleoside transport and increased membrane hydrophobicity. Resistance to anthracyclines in $\text{P388}\text{ADR}$ is associated with an operational barrier to drug retention which was reversed by exposure to the estrogen-bridged adenine derivative. These results suggest further exploration of the estrogen-bridged purines as chemotherapeutic agents.